UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 5, 2015
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
| | | | |
Delaware | | 001-33057 | | 76-0837053 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| |
355 Alhambra Circle Suite 1500 Coral Gables, Florida | | 33134 |
| (Address of principal executive offices) | | (Zip Code) |
| |
| Registrant’s telephone number, including area code: | | (305) 529-2522 |
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On March 5, 2015, the Company issued a press release reporting that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for Firdapse™ for the treatment of Congenital Myasthenic Syndromes.
Additionally, the Company announced that it has received the official minutes from the FDA reporting on the discussions at its formal pre-new drug application (NDA) meeting held earlier this year, and that the minutes confirm the information about the results of the meeting previously reported by the Company in its Form 8-K filed on February 2, 2015.
A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| | 99.1 | Press release issued by the Company on March 5, 2015. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | |
| | | | Catalyst Pharmaceutical Partners, Inc. |
| | | |
| | | | By: | | /s/ Alicia Grande |
| | | | | | Alicia Grande |
| | | | | | Vice President, Treasurer and CFO |
Dated: March 5, 2015
3
